What is Takhzyro?
TAKHZYRO is the #1 prescribed HAE
preventive treatment.
Based on total patients on HAE preventive treatments according to US
third-party industry healthcare data.
In a 6.5-month clinical study of 125 people with HAE 12 years of age and older, people taking TAKHZYRO 300 mg every 2 weeks had
3,250+ PEOPLE IN THE
U.S. PRESCRIBED†
SINCE 2018
after talking to their doctors
FEWER ATTACKS OR
ZERO ATTACKS IN
2 CLINICAL STUDIES
A 6.5-month clinical trial
and a 2.5-year open-label
extension study‡
≤1 MINUTE
TO INJECT
for most people in the
clinical studies§
†Based on 3rd party US specialty pharmacy data. ‡The 6.5-month clinical study included 125 people diagnosed with HAE aged 12 years and older. The main goal of the study was to evaluate the ability of TAKHZYRO 300 mg every 2 weeks to reduce the frequency of HAE attacks. On average, people had 87% fewer attacks compared to placebo. 44% of people had zero attacks for the entire 6.5-month study compared to 2% of those taking placebo. The 2.5-year open-label extension study included 212 people diagnosed with HAE aged 12 years and older. The main goal of this study was to evaluate the long-term safety of TAKHZYRO 300 mg every 2 weeks. Patients knew they were receiving TAKHZYRO, which could have influenced the study results. In this study, people taking TAKHZYRO for an average of 2.5 years had similar results to those in the 6.5-month clinical study. On average, people had 87% fewer attacks compared with baseline. ~69% of people had zero attacks for up to a year. §For people 12 years of age and older taking TAKHZYRO. In clinical studies, the majority of patients self-administered TAKHZYRO over 10 to 60 seconds. These injection times are based on vial administration.
The recommended dose is 300 mg every 2 weeks for people starting on TAKHZYRO.
If you have zero attacks for more than 6 months, your doctor may consider prescribing TAKHZYRO 300 mg once every 4 weeks.
Are you ready to reimagine your life with fewer HAE attacks?
TAKHZYRO was evaluated in 3 clinical studies: a 6.5-month study and a 2.5-year open-label extension study in adolescents and adults, and a 12-month pediatric study.
Explore study results
Want to learn more?
Attending a TAKHZYRO+YOU event is a great way to learn and discover more about TAKHZYRO. You'll hear from healthcare professionals as well as people taking TAKHZYRO.
FIND EVENTS